Simultaneous detection and quantification of angiotensin I, II, 1-7 and 1-9 by LC-MS/MS in human plasma

Recent studies showed that angiotensin-converting 2 (ACE2) is used by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a cellular entry receptor. SARS-CoV-2 causes down regulation of ACE2 leading to renin-angiotensin-aldosterone system (RAAS) major imbalance. This is an essential element of unfavourable evolution in patients with COVID-19. With lower level of ACE2, cleavage of And I and And II is decrease and therefore, And 1-7 and And 1-9 levels are decreased. The development of a quantitative method for these angiotensins is particularly interesting in the context of the prognosis/follow-up of patients with COVID-19. Based on this, this work aims at assessing angiotensins profile variations occurring over time with patients COVID-19 + using a LC-MS/MS method. In this project, plasma samples are prepared with an microelution MAX plate before injection on a Vexera X2 UPLC (Shimadzu Corporation, Kyoto, Japan) coupled to a QT5500 mass spectrometer (Scion, CA, USA) fitted with an IonDriveTMTurbo V ion source and using electro spray ionisation in positive mode. The mobile phase are composed of water (+0,4% formic acid) and of acetonitrile (+0,4% formic acid).